Law Offices of Frank R. Cruz Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders To Inquire About Securities Fraud Class Action

The Law Offices of Frank R. Cruz announced a securities fraud class action on behalf of Unicycive Therapeutics (UNCY) shareholders who purchased stock between December 29, 2025 and June 29, 2026, with a lead plaintiff deadline of November 2, 2026. The suit stems from Unicycive's June 30, 2026 disclosure that the FDA issued a Complete Response Letter on the resubmitted NDA for OLC, citing the same third-party manufacturing deficiencies identified in a June 2025 CRL. On that disclosure, UNCY shares fell $3.01, or 39.1%, to close at $4.69; the complaint alleges the company never inspected or audited its manufacturing vendor's facility for cGMP compliance.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.